Extraordinary General Meeting held in DiaGenic ASA

An extraordinary general meeting of DiaGenic ASA was held on 14 August 2012.

All proposals set out in the notice to the general meeting were approved.

Please minutes from the extraordinary general meeting attached. The minutes will also be posted on

www.newsweb.no and www.diagenic.com

Ingrid Wiik, Chairman

Telephone: +47 900 51 433

e-mail: ingrid@iwiik.com

Henrik Lund, Interim CEO

Telephone: +47 909 71 219

e-mail: henrik.lund@diagenic.com

About DiaGenic ASA

DiaGenic seeks to create value for patients, partners, and investors by developing innovative and more patient friendly methods for early detection of diseases utilizing DiaGenic’s unique concept. The concept implies that a disease evokes systemic responses in the blood unique for the disease, and which can be measured by using blood samples.

DiaGenic is a world leader in identifying these gene expression signatures in peripheral blood and is focused on the development of biomarkers in the field of Alzheimer’s disease and Parkinson’s disease. DiaGenic’s Alzheimer’s disease development program includes the CE marked diagnostic test ADtect®, for detection of mild to moderate Alzheimer’s disease, and MCItect®which is under development for identifying patients with very early stages of Alzheimer’s disease (prodromal AD).

DiaGenic’s concept is protected through an extensive patent portfolio. DiaGenic promotes its products and services towards leading pharmaceutical, imaging and diagnostic companies. DiaGenic is located in Norway and listed on the Oslo Stock Exchange. For more information please visit: www.diagenic.com